Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 8:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
COPD, Chronic Obstructive Pulmonary Disease
Interventions
BIO-11006 Inhalation Solution, Placebo, BIO-11006
Drug
Lead sponsor
BioMarck Pharmaceuticals, Ltd.
Industry
Eligibility
45 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
14
States / cities
Glendale, Arizona • Los Angeles, California • Bay Pines, Florida + 10 more
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
E-Cylinder, Lightweight Cylinder
Device
Lead sponsor
University of Minnesota
Other
Eligibility
40 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Torrance, California + 7 more
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol, Placebo to tiotropium
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 22 more
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Bilevel positive airway pressure (BiPAP)
Device
Lead sponsor
Philips Respironics
Industry
Eligibility
Up to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Lebrikizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 80 Years
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
21
States / cities
Birmingham, Alabama • Peoria, Arizona • Northridge, California + 17 more
Conditions
Obstructive Sleep Apnea, OSA COPD Overlap Syndrome
Interventions
Positive airway pressure, NIPPV and /or oxygen
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years to 89 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
COPD
Interventions
EPIC (Empower People to Independence in COPD), Usual Care
Behavioral · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Asthma
Interventions
AZD7594 DPI 55μg/50μg., AZD7594 DPI 99 µg/90 µg, AZD7594 DPI 198 µg/180 µg, AZD7594 DPI 396 µg/360 µg once daily., AZD7594 DPI 792 µg/720 µg, Placebo for AZD7594 once daily., FF 100 µg once daily (open-label)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 85 Years
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
21
States / cities
Sheffield, Alabama • Phoenix, Arizona • Fullerton, California + 18 more
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo ELLIPTA, Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg, Nemiralisib ELLIPTA 500 µg, Nemiralisib ELLIPTA 750 µg, Albuterol (Salbutamol) MDI or nebules, Standard of care therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Mobile, Alabama • Colorado Springs, Colorado • Daytona Beach, Florida + 17 more
Completed Phase 2 Interventional Results available

28-day Repeat Dose Study of GSK573719

NCT01030965
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK573719 125mcg, GSK573719 250mcg, GSK573719 500mcg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Madisonville, Kentucky • Charlotte, North Carolina • Spartanburg, South Carolina + 1 more
Conditions
COPD, COPD Exacerbation
Interventions
AIRVO
Other
Lead sponsor
Renown Health
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Reno, Nevada
Completed Not applicable Interventional Accepts healthy volunteers

Exercise in Health and Chronic Obstructive Pulmonary Disease

NCT02300064
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Knee-extensor exercise test, Exercise test with restricting/releasing blood flow, Exercise test with variable oxygen concentration and MRI, Exercise test with oral antioxidant or placebo cocktail
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Smoking Cessation
Interventions
placebo, Varenicline Tartarate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 15 more
Conditions
COPD
Interventions
Formoterol Fumarate
Drug
Lead sponsor
Dey
Industry
Eligibility
40 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
44
States / cities
Jasper, Alabama • Phoenix, Arizona • Tuscon, Arizona + 40 more
Conditions
Chronic Bronchitis
Interventions
RheOx Bronchial Rheoplasty, Sham Procedure
Device
Lead sponsor
Gala Therapeutics, Inc.
Industry
Eligibility
35 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 27 more
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Not listed
Lead sponsor
LASARRUS Clinic and Research Center
Industry
Eligibility
21 Years to 100 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland • Salisbury, Maryland
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 85 Years
Enrollment
935 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
92
States / cities
Cullman, Alabama • Jasper, Alabama • Scottsboro, Alabama + 79 more
Conditions
Hypercapnic Respiratory Failure, Chronic Obstructive Pulmonary Disease, Obesity Hypoventilation Syndrome, Sleep Disordered Breathing, Neuromuscular Diseases
Interventions
Vivify, EMS
Other
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Not applicable Interventional

Cognitive Behavioral Therapy for COPD

NCT01694628
Conditions
COPD, Depression
Interventions
CLIMB (COPD Lifestyle, Mood, and Behavior)
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
40 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium, Placebo, GSK573179
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
10
States / cities
Phoenix, Arizona • San Diego, California • Upland, California + 7 more
Recruiting Phase 1 Interventional Accepts healthy volunteers

: Vascular Function in Health and Disease

NCT02966665
Conditions
Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, Hypertension
Interventions
Maximum Exercise Tests, BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate, BQ-123, Fexofenadine, Ranitidine, Angiotensin-II, Valsartan, Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine, BQ-123, MitoQ, BH4
Other · Drug
Lead sponsor
Russell Richardson
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
COPD, Chronic Obstructive Pulmonary Disease, Moderate to Very Severe COPD
Interventions
Aclidinium Bromide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
3,635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
433
States / cities
Birmingham, Alabama • Florence, Alabama • Foley, Alabama + 334 more
Completed Phase 1 Interventional Accepts healthy volunteers

A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)

NCT05830071
Conditions
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions
CHF5993, CHF5259, Moxifloxacin 400mg, CHF5993 Placebo
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 55 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 4 Interventional Results available

Losartan Effects on Emphysema Progression

NCT02696564
Conditions
Emphysema
Interventions
Losartan, Placebo
Drug
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
40 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
28
States / cities
Birmingham, Alabama • Tucson, Arizona • San Diego, California + 18 more